Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors

被引：0
|
作者：
Guimaraes-Young, Amy [1 ]
Davies, Kurtis D. [1 ]
Trevisan, Patricia [1 ]
Nijmeh, Hala [1 ]
Haag, Mary [1 ]
Aisner, Dara L. [1 ]
Patil, Tejas [2 ]
机构：
[1] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA
[2] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA
来源：
JCO PRECISION ONCOLOGY | 2024年 / 8卷
关键词：
KIF5B-EGFR FUSION;
D O I：
10.1200/PO-24-00526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [21] EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations
    Tang, Wenjie
    Li, Xiaolin
    Xi, Xueqi
    Sun, Xindong
    Liu, Jie
    Zhang, Jian
    Wang, Chungang
    Yu, Jinming
    Xie, Peng
    LUNG CANCER, 2019, 136 : 6 - 14
  • [22] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [23] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
  • [24] Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations
    Igawa, Satoshi
    Ryuge, Shiichiro
    Ichinoe, Masaaki
    Nakashima, Hiroyasu
    Otani, Sakiko
    Nakahara, Yoshiro
    Fukui, Tomoya
    Sasaki, Jiichiro
    Kubota, Masaru
    Katagiri, Masato
    Murakumo, Yoshiki
    Satoh, Yukitoshi
    Sato, Yuichi
    Masuda, Noriyuki
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 7 - 13
  • [25] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Giandomenico Roviello
    Laura Zanotti
    Maria Rosa Cappelletti
    Angela Gobbi
    Martina Dester
    Giovanni Paganini
    Chiara Pacifico
    Daniele Generali
    Raheleh Roudi
    Clinical and Experimental Medicine, 2018, 18 : 15 - 20
  • [26] Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
    Singh, Mahaveer
    Jadhav, Hemant R.
    DRUG DISCOVERY TODAY, 2018, 23 (03) : 745 - 753
  • [27] Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer
    Riley, D.
    Kaur, N.
    Baglione, A.
    Hall, R.
    Barnes, L.
    Gentzler, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1092 - S1092
  • [28] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    Current Treatment Options in Oncology, 2016, 17
  • [29] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [30] Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations
    Sugiyama, Eri
    Umemura, Shigeki
    Nomura, Shogo
    Kirita, Keisuke
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Niho, Seiji
    Ohmatsu, Hironobu
    Tsuboi, Masahiro
    Ohe, Yuichiro
    Goto, Koichi
    LUNG CANCER, 2015, 90 (02) : 307 - 313
12345